[go: up one dir, main page]

US3239417A - Methods and compositions for inhibiting sterol biosynthesis - Google Patents

Methods and compositions for inhibiting sterol biosynthesis Download PDF

Info

Publication number
US3239417A
US3239417A US242932A US24293262A US3239417A US 3239417 A US3239417 A US 3239417A US 242932 A US242932 A US 242932A US 24293262 A US24293262 A US 24293262A US 3239417 A US3239417 A US 3239417A
Authority
US
United States
Prior art keywords
compositions
aza
methods
sterol biosynthesis
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US242932A
Inventor
Tullio Nicholas W Di
William L Holmes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Priority to US242932A priority Critical patent/US3239417A/en
Application granted granted Critical
Publication of US3239417A publication Critical patent/US3239417A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom

Definitions

  • the desired result of sterol inhibition is effected without such side effects as fatty infiltration, liver damage, hypertrophy of the adrenals and the like.
  • the phara'maceutical compositions of this invent-ion thus embrace quaternary salts of the above formula.
  • the anionic halide moiety is of relatively minor importance since the properties of the compounds result from the cationic form of the steroidal compound.
  • the anion need only be a pharmaceutically acceptable nontoxic anion and may thus be for example iodide, chloride, bromide and the like.
  • the highly singular properties of these compounds appear to be a function of the structure found in the A and B rings.
  • the cholestane side chain at C-17 is preferred for economic reasons, other compounds containing the various pregnane or testosterone C-17 groups also demonstrate the properties herein described.
  • the preparation of the compounds utilized in this invention is more fully described hereafter. It involves the preparation of a 4-aza-5a-cholestane by treatment of a 3,5-seco-4-norcholestan-5-one-3-oic acid with a lower alkyl amine and subsequent hydrogenation. Introduction of the 3-benzyl group is next accomplished by treatment with benzylmagne-sium bromide followed by hydrogenation. Formation of the quaternary salt is then eifected by standard procedures, such as treatment with a lower alkyl halide.
  • Example 1 3,S-seco-4-norcholestan-5-on-3-oic acid (20 g., 0.05 mole) is dissolved in ml. of absolute alcohol which has been previously saturated with met-hyla-mine. The solution is heated in a pressure vessel at 150 for five hours and then concentrated to about 50 ml. and allowed to cool overnight. The crystals which form are collected to yield 4-methyl-4-aza-5-cholesten-3-one, M.P. 98100.
  • a solution of 10.5 g. of 4-methyl-4-aza-5-cholesten- 3-one in 150 ml. of glacial acetic acid is hydrogenated for 8 hours at 60 and 60 lb./in. pressure in the presence of 100 mg. of platinum catalyst.
  • the solution is then filtered and the solvent distilled.
  • the residue is dissolved in ether and washed with sodium bicarbonate solution and water. After drying the solution over anhydrous sodium sulfate, the ether is removed and the residue crystallized from aqueous alcohol.
  • 4-methyl-4-aza-5a-cholestan-3-one M.P. 118 120".
  • the melting point is raised at l21122 by further crystallization.
  • methylamine may alkyl amine-s in the initial step of this procedure.
  • ExampleZ Ingredients: Amount, mg.
  • talc stearic acid
  • 3-benzyl-4-methyl-4-aza-5ot-cholestane rnethiodide which have previously been passed through a #60 mesh screen.
  • the granulation is'then compressed into tablets employing a flat faced bevel edge single score punch and die.
  • One tablet is administered theree times a day.
  • Example 3 Ingredients: Amount, mg.
  • the above ingredients are mixed and introduced into a #1 hard gelatin capsule.
  • One capsule is administered two times a day.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Description

United States Patent Pennsylvania N0 Drawing. Filed Dec. 7, 1962, Ser. No. 242,932 5 Claims. (Cl. 167-65) Our invention is concerned with methods and compositions for reducing the levels of certain sterol materials from the plasma and organs of animal organisms.
Among the etiological factors for arteriosclerosis is an abnormally-high level of various steroidal lipids, notably cholesterol, in the plasma and organs of the particular subject and it has accordingly been an object of metabolic research to discover agents which would'inhibit the biosynthesis of cholesterol. To a large extent such an objective has been realized with several chemical agents which successfully prevent the formation of cholesterol. It appears however that mere inhibition of cholesterol synthesis not infrequently results in a concomitant and unduly large accumulation in the body of the cholesterol precursor sterols, such as lanosterol, zymosterol and particularly desmosterol.
We have now discovered a method for inhibiting biosynt-hesis of squ-a'lene. Since this substance serves directliy as a precursor in animal organisms for lanosterol, and therefore demosterol and cholesterol, the objective of in hibiting cholesterol biosynthesis without substantial accumulation of squalene, lanosterol, zymosterol and/or desmosterol is thus realized. In short, by virtue of inhibiting the synthesis at an early stage, the precursor thereby not utilized in cholesterol synthesis can be readily utilized by the body in other metabolic pathways. Since the site of inhibition is prior to the synthesis of any steroidal lipid, e.g., as squ'alene biosynthesis, the desired result of sterol inhibition is effected without such side effects as fatty infiltration, liver damage, hypertrophy of the adrenals and the like.
Our method involves the administration of a compound of the formula:
(IJa u lower alkyl lower alkyl advantageously be employed on a bid or t.i.d. basis. quite surprisingly not only do such compositions reduce lipid biosynthesis but in addition they appear to actually reduce absorption of ingested cholesterol from the gastrointestinal tract.
The phara'maceutical compositions of this invent-ion thus embrace quaternary salts of the above formula. The anionic halide moiety is of relatively minor importance since the properties of the compounds result from the cationic form of the steroidal compound. Thus the anion need only be a pharmaceutically acceptable nontoxic anion and may thus be for example iodide, chloride, bromide and the like. In fact, the highly singular properties of these compounds appear to be a function of the structure found in the A and B rings. Thus while the cholestane side chain at C-17 is preferred for economic reasons, other compounds containing the various pregnane or testosterone C-17 groups also demonstrate the properties herein described.
The preparation of the compounds utilized in this invention is more fully described hereafter. It involves the preparation of a 4-aza-5a-cholestane by treatment of a 3,5-seco-4-norcholestan-5-one-3-oic acid with a lower alkyl amine and subsequent hydrogenation. Introduction of the 3-benzyl group is next accomplished by treatment with benzylmagne-sium bromide followed by hydrogenation. Formation of the quaternary salt is then eifected by standard procedures, such as treatment with a lower alkyl halide.
The following examples will further typify the nature of our invention but should not be construed as a limitation thereof.
Example 1 3,S-seco-4-norcholestan-5-on-3-oic acid (20 g., 0.05 mole) is dissolved in ml. of absolute alcohol which has been previously saturated with met-hyla-mine. The solution is heated in a pressure vessel at 150 for five hours and then concentrated to about 50 ml. and allowed to cool overnight. The crystals which form are collected to yield 4-methyl-4-aza-5-cholesten-3-one, M.P. 98100.
. Recrystallization from ethanol produces white needles,
A solution of 10.5 g. of 4-methyl-4-aza-5-cholesten- 3-one in 150 ml. of glacial acetic acid is hydrogenated for 8 hours at 60 and 60 lb./in. pressure in the presence of 100 mg. of platinum catalyst. The solution is then filtered and the solvent distilled. The residue is dissolved in ether and washed with sodium bicarbonate solution and water. After drying the solution over anhydrous sodium sulfate, the ether is removed and the residue crystallized from aqueous alcohol. There is thus obtained 4-methyl-4-aza-5a-cholestan-3-one, M.P. 118 120". The melting point is raised at l21122 by further crystallization.
To a Grignard reagent prepared from 960 mg. (0.04 mole) of magnesium, 20 ml. of dry ether, and 3.8 g. (0.03 mole) of benzyl chloride is added under nitrogen with stirring, 4 g. (0.01 mole) of 4-methyl-4-aza-5acholestan-3-one in 20 ml. of toluene. The ether is removed by warming and an additional 20 ml. of toluene are added. The mixture is refluxed 12 hours and a saturated aqueous solution of ammonium chloride is then added at 0. The organic layer is separated and the aqueous layer extracted with ether. The combined organic extracts are washed with sodium chloride solution and dried over anhydrous sulfate. Removal of the solvent yields a a reddish oil which is very sensitive to air oxidation.
Without .further purification, 4.5 g. of the oil is dissolved in 150 ml. of 95% ethanol and one drop of 10% hydrochloric acid is added. The mixture is treated with hydrogen for 8 hours at 60 and 200 lb./in. pressure in the presence of 500 mg. of platinum catalyst. The catalyst is removed by filtration and the solution allowed to cool overnight. The resulting precipitate is collected and recrystallized from ethyl acetate to yield 3-benzyl-4-methyl- 4-aza-5a-cholestane as white needles, M.P. 122-l23. Two grams of 3-benzyl-4-methyl-4-aza-5a-cholestane is then treated with an excess of methyl iodide in ether. Isolation of the solid and washing with ether then yields the quaternary salt, 3-benzyl-4-methyl-4-aza-5u-cholestane I rnethiodide, M.P. 259260.
Alternatively by using other lower alkyl halides, as'for example ethyl chloride, the corresponding quaternary salts. are obtained.
Similarly methylamine may alkyl amine-s in the initial step of this procedure.
ExampleZ Ingredients: Amount, mg.
3-benzyl-4-methyl-4-aza-5wcholestane rnethiodide 10' Calcium sulfate, dihydrate 200 Sucrose 3'5 Starch 18 Talc 9 Stearic acid 3 The sucrose and calicum sulfate are thoroughly mixed and passed through a #40 mesh screen. Granulation is then effected with a hot 10% gelatin solution andthe wet granulation passed through a #4 mesh screen and dried for three hours at 120 F. The dried granulation is passed through a #14 mesh screen and mixed with the starch,
talc, stearic acid and 3-benzyl-4-methyl-4-aza-5ot-cholestane rnethiodide (which have previously been passed through a #60 mesh screen). The granulation is'then compressed into tablets employing a flat faced bevel edge single score punch and die.
One tablet is administered theree times a day.
. Example 3 Ingredients: Amount, mg.
3-benzyl-4-ethy1-4-aza-Sa-cholestane ethochloride 100 Magnesium stearate l Lactose 400 The above ingredients are passed through a #40 mesh screen, mixed well and introduced into a #40 hard gelatin capsule.
The above ingredients are mixed and introduced into a #1 hard gelatin capsule.
One capsule is administered two times a day.
What is claimed is:
1. The method of reducing stero i y he i n be replaced by other lower animal which comprises administering orally to said mal a compound of the formula:
C H11 CH l Q'CH'Q; V
lower alkyl' lower alkyl wherein X is a pharmaceutically acceptableiwnontoxic halide anion.
2.1The method :of reducing sterol'biosynthesis in an animal which comprises administering orally a pharmaceutical composition comprising a compound of the formula:
C )5 'i 33.3 Xe
lower alkyl lower alkyl CHs' Cs n CH3 hypocholester- References Cited by the Examiner Doorenbos: Drug Trade News, Sept. 3, 1962, pp. 48,
Kenna: I Chem. Soc. March 1960, pp. 945-952.
IULIAN'S. LEVITT,Primary Examiner.
FRANK CACCIAPAGLIA, JRL, LEWIS GOTTS,
. Examiners.
from about 10 mgpto about

Claims (1)

1. THE METHOD OF REDUCING STEROL BIOSYNTHESIS IN AN ANIMAL WHICH COMPRISES ADMINISTERING ORALLY TO SAID ANIMAL A COMPOUND OF THE FORMULA:
US242932A 1962-12-07 1962-12-07 Methods and compositions for inhibiting sterol biosynthesis Expired - Lifetime US3239417A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US242932A US3239417A (en) 1962-12-07 1962-12-07 Methods and compositions for inhibiting sterol biosynthesis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US242932A US3239417A (en) 1962-12-07 1962-12-07 Methods and compositions for inhibiting sterol biosynthesis

Publications (1)

Publication Number Publication Date
US3239417A true US3239417A (en) 1966-03-08

Family

ID=22916684

Family Applications (1)

Application Number Title Priority Date Filing Date
US242932A Expired - Lifetime US3239417A (en) 1962-12-07 1962-12-07 Methods and compositions for inhibiting sterol biosynthesis

Country Status (1)

Country Link
US (1) US3239417A (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887564A (en) * 1973-02-02 1975-06-03 Lilly Co Eli Antibiotic A-25822 and process for production therof
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US4859681A (en) * 1984-02-27 1989-08-22 Merck & Co., Inc. 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5120742A (en) * 1984-02-27 1992-06-09 Merck & Co., Inc. 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5151429A (en) * 1984-02-27 1992-09-29 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α reductase inhibitors
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
US5508852A (en) * 1992-06-17 1996-04-16 Arnold & Richter Cine Technik Gmbh & Co. Drive unit for the adjustment of a zoom, focus or iris diaphragm for camera lenses
US5527807A (en) * 1992-05-20 1996-06-18 Merck & Co., Inc. 7β-substituted-4-aza-5α-cholestan-3-ones as 5α reductase inhibitors useful in the prevention and treatment of hyperandrogenetic disorders
US5536727A (en) * 1992-05-20 1996-07-16 Merck & Co., Inc. 17-Ethers and thioethers of 4-aza-steroids
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5610162A (en) * 1992-05-20 1997-03-11 Merck & Co., Inc. Ester derivatives of 4-aza-steroids
US5620986A (en) * 1992-05-20 1997-04-15 Merck & Co., Inc. 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
US5621104A (en) * 1993-03-24 1997-04-15 Merck & Co., Inc. Substituted 3-phenanthridinone derivatives as 5-alpha-reductase inhibitors
US5629318A (en) * 1992-12-18 1997-05-13 Merck & Co., Inc. Method of treatment of chronic prostatitis with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones
US5639741A (en) * 1992-05-20 1997-06-17 Merck & Co., Inc. 17-amino substituted 4-azasteroid 5α-reductase inhibitors
US5658922A (en) * 1993-06-28 1997-08-19 Merck & Co., Inc. 4-aza-pregnane 5α-reductase isozyme 1 inhibitors
US5763361A (en) * 1995-10-23 1998-06-09 Merck & Co., Inc. 17-alkyl-7-substituted-4-aza steroid derivatives as 5-α-reductase inhibitors
US5843953A (en) * 1994-10-25 1998-12-01 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887564A (en) * 1973-02-02 1975-06-03 Lilly Co Eli Antibiotic A-25822 and process for production therof
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US5120742A (en) * 1984-02-27 1992-06-09 Merck & Co., Inc. 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors
US4859681A (en) * 1984-02-27 1989-08-22 Merck & Co., Inc. 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5151429A (en) * 1984-02-27 1992-09-29 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
US5610162A (en) * 1992-05-20 1997-03-11 Merck & Co., Inc. Ester derivatives of 4-aza-steroids
US5639741A (en) * 1992-05-20 1997-06-17 Merck & Co., Inc. 17-amino substituted 4-azasteroid 5α-reductase inhibitors
US5527807A (en) * 1992-05-20 1996-06-18 Merck & Co., Inc. 7β-substituted-4-aza-5α-cholestan-3-ones as 5α reductase inhibitors useful in the prevention and treatment of hyperandrogenetic disorders
US5536727A (en) * 1992-05-20 1996-07-16 Merck & Co., Inc. 17-Ethers and thioethers of 4-aza-steroids
US5620986A (en) * 1992-05-20 1997-04-15 Merck & Co., Inc. 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
US5508852A (en) * 1992-06-17 1996-04-16 Arnold & Richter Cine Technik Gmbh & Co. Drive unit for the adjustment of a zoom, focus or iris diaphragm for camera lenses
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5629318A (en) * 1992-12-18 1997-05-13 Merck & Co., Inc. Method of treatment of chronic prostatitis with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
US5621104A (en) * 1993-03-24 1997-04-15 Merck & Co., Inc. Substituted 3-phenanthridinone derivatives as 5-alpha-reductase inhibitors
US5658922A (en) * 1993-06-28 1997-08-19 Merck & Co., Inc. 4-aza-pregnane 5α-reductase isozyme 1 inhibitors
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5843953A (en) * 1994-10-25 1998-12-01 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5763361A (en) * 1995-10-23 1998-06-09 Merck & Co., Inc. 17-alkyl-7-substituted-4-aza steroid derivatives as 5-α-reductase inhibitors

Similar Documents

Publication Publication Date Title
US3239417A (en) Methods and compositions for inhibiting sterol biosynthesis
DE3871965T2 (en) STEROID 5 ALPHA REDUCTASE INHIBITORS.
JPH0193600A (en) 17-beta-acyl-4-aza-5 alpha-androstan-1-ene-3- ones as inhibitor of 5 alpha reductase
BRPI0610343B1 (en) Compound derived from morfinan substituted by 6,7-unsaturated 7-carbamoyl, pharmaceutical composition and use thereof
CA2136304A1 (en) Inhibitors of testosterone 5.alpha.-reductase activity
KR960015037B1 (en) 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17-20 lyase inhibitor
SK95894A3 (en) 11-benzaldoxim-17beta-metoxymethyl-estradiene, method of their preparation and treatments containing these compounds
DE69834271T2 (en) STEROID-3-O-SULFAMATE DERIVATIVES AS ESTRONSULFATASE INHIBITORS
JPH01156995A (en) Novel androstane 17-carboxylic acid ester, its production method, and drugs containing the same
US3318926A (en) 7alpha-methyl-16alpha-hydroxy-estrones
EP1599493B1 (en) 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action
US3291690A (en) 25-aza-cholestatrienes, process for production and method of treatment
JPS6355488B2 (en)
JPH09510735A (en) Spirostanil glycosidic crystals
DE1593621A1 (en) 7alpha-methyl-4-androstene and 7alpha-methyl-19-nor-4-androstene and process for their preparation
JPS627200B2 (en)
JPH0678231B2 (en) Blood viscosity reducing agent
EP1594886B1 (en) Antitumoral d-homoestra-1, 3, 5 (10)-trien-3-yl 2-substituted sulfamates
US3639598A (en) Anti-inflammatory compositions and method
US3567713A (en) Derivatives of 2alpha,3alpha-epithioandrostane and process for preparing them
ES2260294T3 (en) 17-METHYLENE-STEROIDS HALOGENATED IN POSITION 4, PROCEDURES FOR THE PREPARATION AND COMPOSITIONS CONTAINING THESE COMPOUNDS.
US3269910A (en) 3(beta-hydroxyethyl)-iminosteroids of the pregnane series and methods of admin-istration
US3214446A (en) 3-(aminoalkoxy)-estra-1, 3, 5(10)-trien-17beta-ol compounds
US20050234027A1 (en) 17alpha-fluorosteroids, pharmaceutical compositions containing 17alpha-fluorosteroids and a method of making them
EP1737880B1 (en) 17alpha-fluoro-17beta-hydroximinomethyl steroids, a method for production thereof and pharmaceutical compositions comprising said compounds